ArticleEMBO molecular medicine2021
Utility of red-light ultrafast optogenetic stimulation of the auditory pathway.
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- All-optical closed-loop control of human cardiomyocyte networks exploiting holographic optogenetics.Communications engineering · 2026Article
- Efficient and sustained optogenetic control of sensory and cardiac systems.Nature biomedical engineering · 2026Article
- Channelrhodopsin variants for high-rate optogenetic neurostimulation at low light intensities.EMBO molecular medicine · 2026Article
- 3D-printed optogenetic neural probe integrated with microfluidic tube for opsin/drug delivery.Scientific reports · 2025Article
- Protein design accelerates the development and application of optogenetic tools.Computational and structural biotechnology journal · 2025Review
- Improved optogenetic modification of spiral ganglion neurons for future optical cochlear implants.Theranostics · 2025Article
- Combined-electrical optogenetic stimulation but not channelrhodopsin kinetics improves the fidelity of high rate stimulation in the auditory pathway in mice.Scientific reports · 2024Article
- Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes.Clinical and translational medicine · 2024Review
- Optogenetics: Illuminating the Future of Hearing Restoration and Understanding Auditory Perception.Current gene therapy · 2024Review
- Review
- Channelrhodopsin fluorescent tag replacement for clinical translation of optogenetic hearing restoration.Molecular therapy. Methods & clinical development · 2023Article
- Light at the end of the tunnel of Corti.Molecular therapy. Methods & clinical development · 2023Article
- A bibliometric profile of optogenetics: quantitative and qualitative analyses.Frontiers in neuroscience · 2023Article
- Patient perspectives on the need for improved hearing rehabilitation: A qualitative survey study of German cochlear implant users.Frontiers in neuroscience · 2023Article
- Is there an unmet medical need for improved hearing restoration?EMBO molecular medicine · 2022Review
- Analyzing efficacy, stability, and safety of AAV-mediated optogenetic hearing restoration in mice.Life science alliance · 2022Article
- Fast Photoswitchable Molecular Prosthetics Control Neuronal Activity in the Cochlea.Journal of the American Chemical Society · 2022Article
- Model-based prediction of optogenetic sound encoding in the human cochlea by future optical cochlear implants.Computational and structural biotechnology journal · 2022Article
- Applications and challenges of rhodopsin-based optogenetics in biomedicine.Frontiers in neuroscience · 2022Review
- Utility of red-light ultrafast optogenetic stimulation of the auditory pathway.EMBO molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optogenetic stimulation of spiral ganglion neurons (SGNs) in the ear provides a future alternative to electrical stimulation used in current cochlear implants. Here, we employed fast and very fast variants of the red-light-activated channelrhodopsin (ChR) Chrimson (f-Chrimson and vf-Chrimson) to study their utility for optogenetic stimulation of SGNs in mice. The light requirements were higher for vf-Chrimson than for f-Chrimson, even when optimizing membrane expression of vf-Chrimson by adding potassium channel trafficking sequences. Optogenetic time and intensity coding by single putative SGNs were compared with coding of acoustic clicks. vf-Chrimson enabled putative SGNs to fire at near-physiological rates with good temporal precision up to 250 Hz of stimulation. The dynamic range of SGN spike rate coding upon optogenetic stimulation was narrower than for acoustic clicks but larger than reported for electrical stimulation. The dynamic range of spike timing, on the other hand, was more comparable for optogenetic and acoustic stimulation. In conclusion, f-Chrimson and vf-Chrimson are promising candidates for optogenetic stimulation of SGNs in auditory research and future cochlear implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.